Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)

Condition studied

Atherosclerotic cardiovascular disease and either overweight or obesity

Investigational medicinal product(s)

Eligibility

Primary endpoint

Time from randomisation to first occurrence of a 4-P composite MACE endpoint consisting of: - CV death - Non-fatal MI - Non-fatal stroke - HF hospitalisationa or urgent HF visit

Endpoint detail

Time from randomisation to first occurrence of an expanded composite 5-P MACE endpoint consisting of: - All-cause death - Non-fatal MI - Non-fatal stroke - HF hospitalisationa or urgent HF visit - Coronary revascularization, Time from randomisation to first occurrence of a composite 3-P MACE endpoint consisting of: - CV death - Non-fatal MI - Non-fatal stroke, Change in eGFR (creatinine and cystatin C-based CKD-EPI 2021) for participants with baseline eGFR<60 mL/min/1.73 m2, Time from randomisation to all-cause death, Time from randomisation to CV death, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI, CCI